Eiger BioPharmaceuticals, Inc. EIGRQ
8.50
0.00
0.00%
as of 1 Oct
- Market cap
- $2.6M
- P/E
- 0.0×
Follow EIGRQ
Growth Flags
show if company had growth for consecutive years
| Dec '23 | Sep '23 | Jun '23 | Mar '23 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.66 | 0.90 | 2.01 | 2.65 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(0.75) | (0.91) | (1.41) | (1.65) | |
P/B ratio |
0.00 | 0.00 | 2.04 | 1.12 | |
Price to Tangible BV |
0.00 | 0.00 | 2.04 | 1.12 | |
EV/Sales |
4.24 | 1.01 | 1.18 | 0.32 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(0.90) | (0.18) | (0.20) | (0.05) | |
EV/FCF |
(0.90) | (0.18) | (0.20) | (0.05) | |
Quick Ratio |
0.51 | 2.47 | 3.43 | 3.30 | |
Current Ratio |
0.71 | 3.31 | 4.22 | 4.04 | |
Net Debt/EBITDA |
(1.24) | (0.09) | 0.64 | 1.54 | |
Debt/Assets |
105.91% | 73.56% | 56.21% | 40.74% | |
Debt/Equity |
(2.84) | (25.52) | 2.66 | 1.15 | |
Asset Turnover |
0.20 | 0.15 | 0.13 | 0.12 | |
Operating CF/Net income |
1.04 | 0.81 | 1.06 | 1.05 | |
Capex/Depreciation |
0.11 | 0.00 | 0.05 | 0.72 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
305.39% | 453.97% | 417.85% | 406.70% | |
Selling, General and Administrative Expense of Revenue |
123.64% | 169.96% | 119.17% | 231.06% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
17.96% | 32.35% | 16.05% | 61.73% | |
Graham Net Nets |
(1.48) | (0.20) | 0.43 | 0.83 | |
Graham Number |
106.11 | 38.03 | 0.00 | 0.00 | |
Earnings Yield |
(723.58%) | (659.52%) | (309.97%) | (247.74%) | |
Free Cash Flow Yield |
(715.72%) | (627.68%) | (286.35%) | (224.75%) | |
Revenue per Share |
2.58 | 2.17 | 3.15 | 2.80 | |
Operating CF per Share |
(9.45) | (9.86) | (14.94) | (16.33) | |
Capex per Share |
0.00 | 0.00 | (0.01) | (0.15) | |
Free Cash Flow per Share |
(9.45) | (9.86) | (14.95) | (16.48) | |
Cash per Share |
17.24 | 26.71 | 36.34 | 51.20 | |
Shareholders Equity per Share |
(9.80) | (1.09) | 10.37 | 23.97 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(9.80) | (1.09) | 10.37 | 23.97 | |
Free Cash Flow |
(13.95) | (14.55) | (22.05) | (24.22) | |
Working Capital |
(15.44) | 38.10 | 53.77 | 72.91 | |
Capital Expenditures |
0.00 | 0.00 | (0.02) | (0.22) | |
Net Current Asset Value |
(15.44) | (2.63) | 13.42 | 32.92 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.05 | |
Net Profit Margin |
(353.77%) | (561.86%) | (445.72%) | (553.28%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1.72 | 1.89 | 2.38 | 3.09 | |
Average Payables |
5.55 | 7.68 | 7.45 | 10.54 | |
Average Inventory |
2.20 | 1.96 | 1.99 | 3.62 | |
Average Assets |
79.48 | 99.70 | 118.02 | 126.28 | |
Average Common Equity |
20.43 | 38.35 | 59.11 | 66.25 |
Columns are period end dates